TFX Teleflex Incorporated

Teleflex to Present Innovative Interventional Access Technologies at the Annual Meeting and Postgraduate Course of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), to be Held in Barcelona, Spain on September 10-13, 2016

Teleflex Incorporated (NYSE: TFX) a leading global provider of medical devices for critical care, urology and surgery will showcase two of its advanced Arrow® Interventional Access Products at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Barcelona.

During the event, Teleflex will highlight both the Arrow® OnControl® Powered Bone Access System and the ARROW-Clark™ VectorFlow™ Chronic Hemodialysis Catheter, together with other technologically advanced products for interventional applications.

The Arrow® OnControl® Powered Bone Access System offers the ability to effectively1, safely and rapidly2 obtain high quality bone samples. Our bone lesion biopsy needle is designed specifically for multiple bone biopsies from a single cortical penetration. Using Teleflex’s patented handheld driver technology, the Arrow® OnControl® Powered Bone Access System provides interventional radiologists a fast reliable3 solution for accessing dense and hard-to-reach bone lesions.

The ARROW-Clark™ VectorFlow™ Catheter is the only catheter with an innovative tip designed to produce a helical, three-dimensional transition of blood entering and leaving the catheter.4 Designed for optimum performance, the ARROW-Clark™ VectorFlow™ Catheter (available in both retrograde and antegrade insertion platforms) is a tunneled hemodialysis catheter with symmetrical tip that is designed to reduce loss of lock solution (a contributing factor in reducing the risk of thrombus adherence), gives sustained high flows, minimizes recirculation and reduces the risk of platelet damage resulting from shear stress.5

During the CIRSE Congress on Sunday, September 11 and Monday, September 12, at 14:00 Prof. Dr. med. Roman Fischbach, Head of Radiology and Neuroradiology at Asklepios Klinik Altona, will lead in-booth sessions entitled "CT guided bone biopsy with the Arrow® OnControl® Powered Bone Access System. Clinical applications, technique and results."

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, ARROW-Clark, Deknatel, Hudson RCI, LMA, OnControl, Pilling, Rüsch, VectorFlow and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2016 Teleflex Incorporated. All rights reserved.

References:

1. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematology Reports 2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free article] [PubMed] verified March 2015.

2. Lee RK, Ng AW, Griffith JF. CT-guided bone biopsy with a battery-powered drill system: preliminary results. AJR Am J Roentgenol 2013;201(5):1093-5. doi:10.2214/AJR.12.10521. Available at: [PubMed] verified March 2015.

3. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematology Reports 2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free article] [PubMed] verified March 2015.

4. Clark T, et al. Computational Flow Dynamics and Preclinical Assessment of a Novel Hemodialysis Catheter. Seminars in Dialysis 2012;25(5):574-581. doi: 10.1111/j.1525-139X.2012.01052.*

5. Clark TWI, Isu G, Gallo D, Verdonck P, Morbiducci U. Comparison of symmetric hemodialysis catheters using computational fluid dynamics. Journal of Vascular and Interventional Radiology. 2015;26(2):252-259. doi: 10.1016/j.jvir.2014.11.004

EN
09/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex Announces Second Quarter 2025 Earnings Conference Call Inform...

Teleflex Announces Second Quarter 2025 Earnings Conference Call Information WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, . An audio replay of the call will be available beginning at 11:00 am Easter...

 PRESS RELEASE

Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Bu...

Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establi...

 PRESS RELEASE

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhex...

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guin...

 PRESS RELEASE

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Thro...

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and th...

 PRESS RELEASE

Teleflex Publishes 2024 Global Impact Report

Teleflex Publishes 2024 Global Impact Report Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Cl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch